Marbofloxacin suspension and preparation method thereof

A technology of marbofloxacin and suspension, applied in liquid delivery, pharmaceutical formula, emulsion delivery, etc.

Inactive Publication Date: 2018-03-23
HUBEI LONGXIANG PHARMA TECH CO LTD
View PDF3 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, marbofloxacin is insoluble in water, and currently there are only injections and soluble powder preparations in China

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Marbofloxacin suspension and preparation method thereof
  • Marbofloxacin suspension and preparation method thereof
  • Marbofloxacin suspension and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0023] The specification of the marbofloxacin suspension provided in this example is 10 mL per vial, and each vial contains 0.1-0.5 g of the main drug. In this embodiment, the preparation method of the marbofloxacin suspension is as follows: first, weigh each component according to the following formula:

[0024]

[0025] Then the suspending agent CMC-Na (sodium carboxymethylcellulose) and xanthan gum are dissolved in partly purified water for later use, and then the wetting agent PEG400 (polyethylene glycol 400) is dissolved with partly purified water, and Mabo is added Stir evenly after the Floxacin to obtain a Marbofloxacin suspension; add the suspending agent solution to the Marbofloxacin suspension to obtain a mixed solution; finally use the remaining purified water to dissolve the preservative sodium benzoate, sweetener stevioside, flocculation Sodium citrate as an agent and natural essence as an aromatic agent, the obtained solution is added to the mixed liquid, and ...

Embodiment 2

[0027] The specification of the marbofloxacin suspension provided in this example is 10 mL per vial, and each vial contains 0.1-0.5 g of the main drug. In the present embodiment, the preparation method of the marbofloxacin suspension is the same as in Example 1, except that the components in the present embodiment are as follows:

[0028]

[0029]

Embodiment 3

[0031] The specification of the marbofloxacin suspension provided in this example is 10 mL per vial, and each vial contains 0.1-0.5 g of the main drug. In the present embodiment, the preparation method of the marbofloxacin suspension is the same as in Example 1, except that the components in the present embodiment are as follows:

[0032]

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides a Marbofloxacin suspension. Marbofloxacin is taken as main medicine in the suspension, and the Marbofloxacin suspension at least comprises the following components in parts by weight: 100 parts of Marbofloxacin, 30 to 40 parts of a suspending agent, 0.5 to 2 parts of a preservative, 10 to 20 parts of a wetting agent, 0.5 to 2 parts of a flavoring agent, 2 to 8 parts of a sweetening agent and 3000 to 4000 parts of purified water. The invention also provides a preparation method of the Marbofloxacin suspension. According to the Marbofloxacin suspension, which is high in stability, high in quality, obvious in curative effect and little in adverse reaction, prepared by taking Marbofloxacin as main medicine and the preparation method thereof provided by the invention, theMarbofloxacin suspension prepared by using the method, namely insoluble solid medicine, is dispersed in a liquid medium.

Description

technical field [0001] The invention belongs to the field of veterinary drug suspensions, in particular to a suspension containing marbofloxacin, a veterinary antibiotic drug, and a preparation method thereof. Background technique [0002] Marbofloxacin is a third-generation quinolone antifungal drug. It inhibits the growth of bacteria by inhibiting bacterial DNA transcriptase. It has antibacterial effects on Gram-negative bacteria, Gram-positive bacteria and mycoplasma. It can be administered orally and Injection administration can be well absorbed, and the toxic and side effects are low. Moreover, when the drug is used as a veterinary drug, adverse reactions rarely occur, and it is still effective for drug-resistant pathogenic bacteria such as erythromycin, lincomycin, chloramphenicol, doxycycline, and sulfa drugs. [0003] Marbofloxacin has been widely used in the European Union, New Zealand, Japan and other countries, and the main dosage form is injection. Marbofloxaci...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/10A61K47/38A61K47/36A61K31/5395A61P31/04
CPCA61K9/10A61K31/5395A61K47/36A61K47/38
Inventor 陈清平熊玲玲吴东林王铭宏
Owner HUBEI LONGXIANG PHARMA TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap